Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma
5-Aminolevulinic acid (5-ALA) has become an important assistant in glioblastoma (GB) surgery. Unfortunately, its price affects its widespread use.
The aim of this study was to compare commercial 5-ALA with the pharmacy-compounded solution.
Using first an in vitro experimental approach, different concentrations of the pharmacy-compounded solution and commercial 5-ALA were tested in U87MG, LN229, U373, and T98G commercial glioblastoma cell lines. Fluorescence intensity was compared for each concentration by flow cytometry. Mean fluorescence of culture supernatant and lysate samples were analyzed. In a second phase, both preparations were used for surgical glioblastoma resection and tumor samples were analyzed by confocal microscopy. Mean fluorescence intensity was analyzed for each preparation and compared.
There was a high variability of fluorescence intensity between cell lines, but each cell line showed similar fluorescence for both preparations (compounded preparation and commercial 5-ALA). In the same way, both preparations had similar fluorescence intensity in glioblastoma samples.
Both, compounded and commercial 5-ALA preparations produce equivalent fluorescent responses in human glioblastoma cells. Fluorescence intensity is cell line specific, but fluorescent properties of both preparations are undistinguishable.
KeywordsAminolevulinic acid Glioblastoma Fluorescence
- 4.Della Puppa A, Ciccarino P, Lombardi G, Rolma G, Cecchin D, Rosetto M (2014) 5-Aminolevulinic acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patterns. Biomed Res Int 2014:232561Google Scholar
- 6.Díez Valle R, Tejada Solis S, Idoate Gastearena MA, García de Eulate R, Domínguez Echávarri P, Aristu Mendiroz J (2011) Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. Neurooncol 102:105–113CrossRefGoogle Scholar
- 11.Juzeniene A, Kaliszewski M, Bugaj A, Moan J (2009) Clearance of protoporphyrin IX induced by 5-aminolevulinic acid from WiDr human colon carcinoma cells. Proc of SPIE 7380Google Scholar
- 13.Kim JE, Cho HR, Xu WJ et al (2015) Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget 6:20266–20277Google Scholar
- 26.Roberts DW, Valdes PA, Harris BT et al (2011) Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 114:595–603CrossRefGoogle Scholar
- 29.Schebesch KM, Brawanski A, Hohenberger C, Höhne J (2016) Fluorescein sodium-guided surgery of malignant brain tumors: history, current concepts, and future projects. Turk Neurosurg 26:185–194Google Scholar
- 41.Valdes PA, Bekelis K, Harris BT et al (2014) 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo. Neurosurgery 10:74–82Google Scholar
- 43.Valdes PA, Kim A, Brantsch M et al (2011) δ-Aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy inhuman gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro-Oncology 13:846–856CrossRefGoogle Scholar